Dr Thomas Webster
Hebei University of Technology, USA [Nominated for the Nobel Prize in Chemistry (2023)]
Dr Thomas Webster
Hebei University of Technology, USA [Nominated for the Nobel Prize in Chemistry (2023)]
Thomas J. Webster’s (H index: 118; Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has served as a professor at Purdue (2000-2005), Brown (2005-2012), and Northeastern (2012-2021; serving as Chemical Engineering Department Chair from 2012 - 2019) Universities and has formed over a dozen companies who have numerous FDA approved medical products currently improving human health. He is currently helping those companies and serves as a professor at Hebei University of Technology, Saveetha University, Vellore Institute of Technology, UFPI, and others. Dr. Webster has numerous awards including: 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Materials Science and Mixed Fields); 2021, Clarivate Top 0.1% Most Influential Researchers (Pharmacology and Toxicology); 2022, Best Materials Science Scientist by Citations (Research.com); and is a fellow of over 8 societies. Prof. Webster is a former President of the U.S. Society For Biomaterials and has over 1,350 publications to his credit with over 53,000 citations. He was recently nominated for the Nobel Prize in Chemistry (2023).
Kalliopi Megari
Professor at School of Psychology Aristotle University of Thessaloniki, Greece
Kalliopi Megari
Professor at School of Psychology Aristotle University of Thessaloniki, Greece
Dr. Kalliopi Megari is an experienced neuropsychologist working in the hospital & health care industry. Skilled in Clinical Neuropsychology, Clinical Research and Learning Disabilities. Graduated from Aristotle University of Thessaloniki and attended further education from University of Macedonia, in people with special needs and disabilities. She holds undergraduate degrees in Nursing and Psychology, as well as a Masters and a PhD in Neuropsychology from Aristotle University of Thessaloniki. She has many years of experience working with cancer and cardiac surgery patients as well with people with disabilities. She is postdoctoral researcher she has many research articles and participated in many international conferences. Her work has earned her many prestigious international awards. She has given lectures at Aristotle University of Thessaloniki and University of Warsaw. She is the Global Engagement Representative of International Neuropsychological Society and General Secretary and member of the Ethics Committee of Hellenic Neuropsychological Society
Christian Lavarreda
Global Product Manager - Pure Media at Syntegon, Germany
Christian Lavarreda
Global Product Manager - Pure Media at Syntegon, Germany
Christian Lavarreda, based out of Dresden, Germany, is currently global product manager for pure media, process, and bioprocess systems at Syntegon (formerly Bosch Packaging Technology). Formally trained as a chemical engineer, he is responsible for leading the development, commercialization, and marketing of Syntegon’s pharmaceutical liquid processing portfolio. Prior roles at Syntegon have also included regional business development and marketing manager for liquid pharmaceutical primary packaging in North America. During his seven years at Syntegon, Christian has utilized his expertise to connect customer needs to Syntegon’s capabilities while helping manage account relationships to ensure customer success and satisfaction. Christian also has a background in inhalable drug product development, where he spent twelve years leading R&D and commercialization activities of analytical instrumentation for the delivered-dose uniformity and particle size characterization of dry powder, metered-dose, nebulizer, and nasal inhalers. He has multiple peer-reviewed publications on the application of cascade impaction technology for the characterization of aerosolized medicines.
Dr Thomas Hauser
Sales Director EMEA, C-CUBE, Germany
Dr Thomas Hauser
Sales Director EMEA, C-CUBE, Germany
Thomas Hauser (*1967) is working since June 2023 for C-CUBE as a Sales Director in the EMEA region to educate the market for offsite prefabricated and prequalified turn-key factory and smart module concept in a drive to bring forward the pharmaceutical facility of the future concept.
In his former work for G-CON and his consulting agency, he has supported companies in the life science segment mainly for expansion strategies, strategical facility implementation, start-up support and pharmaceutical packaging supply and technologies, in particular in questions of manufacturing set-up.
Before 2020, Thomas worked in various leading global positions in Business Development, Strategic Implementation and Sales in the Pharmaceutical Packaging field, namely in injectables, semi solid and oral solid packaging. He has more than 25 years of experience dealing with the global Lifesciences Industry and their market and manufacturing requirements.
Thomas holds an International MBA from the University of Ottawa / Canada, and a BA for European Business from the ESB Reutlingen and the ESC Reims.
Matthias Angelmaier
Senior Project Engineer and Global Technology Partner for Fill-Finish at Pharmaplan, Germany
Matthias Angelmaier
Senior Project Engineer and Global Technology Partner for Fill-Finish at Pharmaplan, Germany
Matthias Angelmaier is a Senior Project Engineer and Global Technology Partner for Fill-Finish at Pharmaplan. He joined the company in August 2022.
His previous positions were at a multinational processing and packaging technology solutions provider where he started in 2009 as a project manager for handling complex customer projects. Since 2012 he was global responsible product manager for aseptic fill-finish, barrier and Isolator systems as well as process technology.
His expertise includes process engineering, sterilization, biodecontamination, aseptic and high-potent Isolator applications, GMP and HSE-related fill-finish applications as well as topics related to advanced aseptic processing.
He has a bachelor’s degree in industrial and mechanical engineering as well as a master’s degree in business development.
Dr. Gunjan Bhardwaj
Founder & CEO at Partex NV, Germany
Dr. Gunjan Bhardwaj
Founder & CEO at Partex NV, Germany
Dr Gunjan Bhardwaj is the Founder and CEO of the Partex NV World's largest AI powered Drug Assets Manager – Solving the inefficiency problem of Life Sciences Industry in drug discovery & development using Big Data & Artificial Intelligence.
He is member of various AI Think tanks as well as a Not for Profit focused on Sustainability. He is also Founder of Innoplexus AG: an AI champion in the life science Industry.
He worked as an Adjunct professor at Pforzheim University, Germany.
He has led projects in strategy, analytics and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry.
He having 18+ patents related to AI & Blockchain, Published 2 books in Branding and Drug Discovery respectively as well as a number of publications in Harvard Business Review, Journal of Service Research, MIT Sloan Review etc. Gunjan’s work has been covered by various Newspapers, Business magazines and he has been a keynote speaker in various international event. He has 40 under 40 Award by Capital Magazine in Germany.
BCG-Handelsblatt young leader of future reality Award Top 30 most influential people of the new normal by Germany’s Focus Magazine. Excellent Leader with an Immigration Background Award by City of Frankfurt, Germany.
DOĞAN TAŞKENT
R&D and Innovation at Atabay Pharmaceuticals and Fine Chemicals Inc., Turkey
DOĞAN TAŞKENT
R&D and Innovation at Atabay Pharmaceuticals and Fine Chemicals Inc., Turkey
After graduating from ETH Zürich with a degree in Electrical Engineering in 1993, Mr. Taskent joined MIT for research and Polytechnic Institute of New York University for the Electrophysics and Technology MBA degrees.
During 1998-2005, he worked as a R&D engineer, expert consultant and instructor at Lucent Technologies Bell Laboratories. During that timeframe he led major fiberoptic transmission system deployments. During 2006-2007 worked as CTO at the Lucent Technologies Istanbul Office. 2008-2018 worked at Arkan & Ergin Corporate Finance, focusing startup valuation, development of Turkish startup ecosystem and growing the technology transfer environment. Since 2019 has been working at Atabay Pharmaceuticals and Fine Chemicals as director responsible for R&D and innovation. Academically, teaching MBA students on technology and innovation management at Koç University since 2012.
He is the founding President of MIT Enterprise Forum in Turkey, was member at the Advisory Board of the Endeavor Turkey and founding Board member of the Ege University Technopark. He has been Chairman of the Board at the Swiss Chamber of Commerce in Turkey and also the Vice-President at the Foreign Economic Relations Board (DEIK) responsible for Switzerland.
Currently serving as the Board Member at the Global Relations Forum, at the University Industry Relationships Platforms, and at Izmir Biomedicine and Genome Center.
Miloš Milenković
Strategic Partnering Chapter Head & CEETRIS region, Established Products Lead at Roche, Serbia
Miloš Milenković
Strategic Partnering Chapter Head & CEETRIS region, Established Products Lead at Roche, Serbia
Mr Miloš Milenković is currently working as a Strategic Partnering Chapter Head & CEETRIS region Established Products Lead at Roche, Serbia. He also worked as a Commercial Affairs Lead in Turkey, Strategic Partnership Lead, Commercial and Partnering, Head Business Development & Commercial Manager in Roche & GlaxoSmithKline (GSK).
He having more than 20 years of experience in Pharma industries. He is graduate in pharmacy & post graduate in MBA from Frankfurt School of Finance and Management, Frankfurt, Germany.
Dr. Sawsan Al Madhi (MD)
Advocacy Advisor, Founder and CEO of AlignnEficient Health Consultancies, UAE, UK
Dr. Sawsan Al Madhi (MD)
Advocacy Advisor, Founder and CEO of AlignnEficient Health Consultancies, UAE, UK
Dr. Al Madhi is an Internal Medicine specialist, Fellow of The Royal Society of Medicine (London), and a registered doctor with the General Medical Council (GMC) in the United Kingdom. She is a professional healthcare Leader and Consultant, Advocacy Advisor, Entrepreneur, honor class master’s degree holder and an MD with more than 20 years’ progressive leadership experience and skills in strategy, governance, operations and administration within the civil society, not-profit charitable sector, advocacy and public health education & promotion within UAE and internationally. Other areas of expertise include: public speaking and academia. Currently she is the founder and CEO of Alignn Eficient Health Consultancies a niche social enterprise working with multi stakeholders to push the agenda of advocacy on a local, regional and global level while focusing on patient’s centricity and meaningful engagement of the patient’s voice. Previously working in one of the most reputable charities in the UAE as the Director General for Friends of Cancer Patients, Dr. Sawsan’s role was to supervise the continuing refinement and expansion of the organizational objectives which include: providing high quality services, organizing fundraising activities, developing, planning and executing nationwide awareness programs and campaigns through collaboration with a vast network of national and international, governmental and private sector organizations, pushing the advocacy agenda on NCD's and working on feasible patients access to treatment solitons.
Casten Jasper
Director, Validations & Systems Operations Europe & Asia at Charles River Laboratories Microbial Solutions, Germany
Casten Jasper
Director, Validations & Systems Operations Europe & Asia at Charles River Laboratories Microbial Solutions, Germany
Casten Jasper is currently working as a Director, Validations & Systems Operations Europe & Asia at Charles River Laboratories Microbial Solutions. He having 15 years of experience in Biotechnology field. In his current role he is responsible for defining and implementing strategies and processes for GMP-compliant processes and systems at the European Microbial Solutions sites. He also serves as a subject matter expert for internal development projects and is member of various industry communities.
Badre E. Hammond
Global VP, Commercial Operations and GM at Aptar Pharma, USA
Badre E. Hammond
Global VP, Commercial Operations and GM at Aptar Pharma, USA
Badre E. Hammond is Global VP, Commercial Operations and GM at Aptar Pharma, USA. His background is in Biochemistry with 20 years’ experience in pharmaceutical product development with focus on pulmonary drug delivery systems. Mr. Hammond has broad experience in managing development of novel drug product programs for the pharmaceutical market from formulation development, pre-clinical, CMC, to clinical phase. After acquiring an MBA, Mr. Hammond took the position of head of Business Development at Next Breath. In this capacity he played a central role in supporting product development program’s CMC requirement by designing experiments, consulting, and guiding programs through US and international regulatory landscape.
Dr. Raghuram Selvaraju
Managing Director of Equity Research at H.C. Wainwright & Chairman of the Board at Relief Therapeutics Holding AG, USA
Dr. Raghuram Selvaraju
Managing Director of Equity Research at H.C. Wainwright & Chairman of the Board at Relief Therapeutics Holding AG, USA
Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright - a full-service investment bank headquartered in New York City - whose research focuses on the healthcare sector, particularly pharmaceutical and biotechnology companies and programs. He is also Chairman of the Board at Relief Therapeutics Holding AG, a publicly-listed commercial-stage biopharmaceutical company headquartered in Geneva, Switzerland. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. In 2021, Dr. Selvaraju was the top analyst in the world across all sectors according to TipRanks based on portfolio return. Dr. Selvaraju was ranked by both StarMine for his earnings accuracy and by The Wall Street Journal’s annual Best on the Street survey for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he has extensively discussed drug development trends, healthcare reform policy, and pharma/biotech M&A. Prior to joining H.C. Wainwright, Dr. Selvaraju held Senior Research positions at MLV & Co., Aegis Capital, Hapoalim Securities USA (the U.S. broker/dealer arm of Bank Hapoalim B.M., Israel’s largest financial services group) and Rodman & Renshaw LLC. He was Head of Healthcare Equity Research at both Aegis Capital and Hapoalim Securities and established the equity research division at Aegis Capital. Dr. Selvaraju’s educational background includes a Ph.D. in molecular neuroscience and cellular immunology, an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an MBA from the Johnson Graduate School of Management at Cornell University. He obtained a B.S. degree from Carnegie Mellon University in Pittsburgh, PA with a dual major in cell, molecular and developmental biology and technical writing.
Dr Orestis Ioannidis
Surgeon at General Hospital "George Papanikolaou", Thessaloniki, Greece
Dr Orestis Ioannidis
Surgeon at General Hospital "George Papanikolaou", Thessaloniki, Greece
Dr. Ioannidis studied medicine in the Aristotle University of Thessaloniki and graduated at 2005. He received his MSC in “Medical Research Methodology” in 2008 from Aristotle University of Thessaloniki and in “Surgery of Liver, Biliary Tree and Pancreas” from the Democritus University of Thrace in 2016. He received his PhD degree in 2014 from the Aristotle University of Thessaloniki for his thesis “The effect of combined administration of omega-3 and omega-6 fatty acids in ulcerative colitis. Experimental study in rats.” He is a General Surgeon with special interest in laparoscopic surgery and surgical oncology and also in surgical infections, acute care surgery, nutrition and ERAS. He has received fellowships for EAES, ESSO, EPC, ESCP and ACS and has published more than 130 articles with more than 3000 citations and an H-index of 28.
Dr Mihail Lucian Birsa
Professor at "Alexandru Ioan Cuza" University of Iasi, Romania
Dr Mihail Lucian Birsa
Professor at "Alexandru Ioan Cuza" University of Iasi, Romania
Dr. Mihail Lucian Birsa is currently a Professor in the Department of Chemistry at the Alexandru Ioan Cuza University of Iasi, Romania. In 2003 he was selected as a member of the Alexander von Humboldt Foundation, working with Professor Henning Hopf in TU Braunschweig - Germany. Since then numerous return fellowships were granted by the Alexander von Humboldt Foundation. He has more than 120 publications in peer-review journals and published +45 books/book chapters (John Wiley & Sons, Thieme etc). Also, is editorial board member in more than 50 journals.
Dr. Laura Gabriela SARBU
Professor at "Alexandru Ioan Cuza" University of Iasi, Romania
Dr. Laura Gabriela SARBU
Professor at "Alexandru Ioan Cuza" University of Iasi, Romania
Dr. Laura Gabriela SARBU is currently an Associate Professor in the Department of Chemistry at Alexandru Ioan Cuza University of Iasi, Romania. She received a Ph.D. degree in Organic Chemistry in 2015. During the Ph.D. program she joined several times the Prof. dr. Henning Hopf research team in TU Braunschweig – Germany. She has more than 40 publications in peer-review journals and published 4 books. Also, is editorial board member in 25+ journals.
Kiokias Sotirios
European Research Executive Agency, Belgium
Kiokias Sotirios
European Research Executive Agency, Belgium
Dr Sotirios Kiokias is a PhD in the area of Food Chemistry and Nutrition (University of Reading/UK). In his early career (2002-2006) he performed EU funded postdoctoral research at Unilever R&D (The Netherlands) and National Technical University of Athens. In the period 2006-2016 he was employed as scientific expert by various EU Institutions (DG Enterprise & European Chemicals Agency/Finland). Since 2017, Dr Kiokias is a Research Program manager at the European Research Executive Agency of European Commission (Brussels), serving as the Coordinator of Chemistry Panel in MSCA-Staff exchanges Action. Dr Kiokias has published more than 40 scientific publications in international journals/book chapters and participated in a large number of International Food & Chemistry relevant Conferences
Ralf Aubeck
Principal Consultant and Industry Certified GMP Auditor at Gempex GmbH, Germany
Ralf Aubeck
Principal Consultant and Industry Certified GMP Auditor at Gempex GmbH, Germany
Ralph Aubeck works worldwide for Gempex GmbH as Principal Consultant and Industry Certified GMP Auditor. He studied chemistry at the Ludwig-Maximilians-University in Munich and received his PhD in 1991. re. of course via chemical-pharmaceutical biosensors. More than 28 years of experience in responsible positions in quality management in German and American small and medium-sized industrial companies as well as large corporations in Germany and Switzerland form the foundation of his practical expertise.
Marià Alemany Lamana
Emeritus Professor of Biochemistry / Nutrition, University of Barcelona, Spain
Marià Alemany Lamana
Emeritus Professor of Biochemistry / Nutrition, University of Barcelona, Spain
Marià Alemany Lamana (Barcelona, 1946) has been professor of nutrition and biochemistry at the Faculty of Biology of the University of Barcelona. He has been an emeritus professor since 2016.
Degree in Biology from the University of Barcelona (1968), where he also obtained a doctorate in Biological Sciences (1972) with the thesis " Algunos aspectos del metabolismo del glucógeno en el mejllón ("Mytilus edulis" L.) ". He did postdoctoral studies (1973-74) at Washington University in St. Louis, in the United States.
Professor at the University of Barcelona (1968-1977), University of the Balearic Islands (1977-1982), University of Barcelona in Tarragona (1982-1986) and once again at the University of Barcelona, where he has been professor at the Faculty of Biology from 1986 until his retirement in 2016. He has also been assistant professor of Physiology (1974), associate (1977) and professor of Biochemistry (1981, 2012), Nutrition (2001).
He has published several technical, lexicographic, essay and dissemination books, as well as fiction.
Gurpreet Singh
Vice President, Managing Director Integrated Safety at IQVIA, UK
Gurpreet Singh
Vice President, Managing Director Integrated Safety at IQVIA, UK
Gurpreet Singh is currently the Vice President, Managing Director Integrated Safety at IQVIA. He is based in UK and has a total of 18 years' experience in Pharma Industry of which 16+ years have been in Global Drug Development. During these years he has had the opportunity to work with some top Global companies like Cognizant, Tata Consultancy, Novartis and Parexel. At Novartis he was the Global Head of PV Operations managing all Global PV activities. At Parexel he was the Senior Director PV Operations responsible for managing PV projects of top Global Pharma and Biotech companies. Gurpreet is a certified Six Sigma and Project Management Professional. He has keen interest in Digital Transformation and Organization Culture and has successfully led various projects during his tenure in the Pharma Industry. He is an avid runner and a speaker at various Pharma conferences
Dr Marco Penske
Head Market Access & Healthcare Affairs Boehringer Ingelheim, Germany
Dr Marco Penske
Head Market Access & Healthcare Affairs Boehringer Ingelheim, Germany
Dr Marco Penske has been the Head of Market Access and Healthcare Affairs at Boehringer Ingelheim since 2011. Dr Penske studied Economics at Johannes Gutenberg University Mainz, focussing on Health Economics and Statistics. Afterwards, he worked as a research assistant for the chair of Finance and Economics at the university. Following his promotion in the field of healthcare systems, he was employed at a business consultancy company. In 2007, he joined Boehringer Ingelheim and gained experience within several Market Access functions. In his current role, he is responsible for benefit assessments and price negotiation in accordance with AMNOG, developing pricing strategies and contract models for pharmaceuticals, health economics and outcomes research as well as key account management and healthcare affairs activities. In addition, he is an active speaker at congresses and works as a lecturer.
Luca Roncati
University of Modena and Reggio Emilia, Italy
Luca Roncati
University of Modena and Reggio Emilia, Italy
Luca Roncati, Italian pathologist, physician-scientist, anti-cancer patent inventor, academic editor, medical lecturer, and award-winning author with more than 260 publications to his credit, specialized in gynaecologic oncology, paediatric pathology, hematopathology and soft tissue tumours, eponym of Roncati-Manenti triad, describer of T rex lymphoma, pioneering researcher in COVID-19, leading researcher in nanopathology, forensics expert and adjunct professor of Anatomical Pathology at the University of Modena and Reggio Emilia (Italy).